ClinicalTrials.gg
RecruitingNCT06007404Updated Oct 15, 2026

Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents

An observational study in Type 2 Diabetes, Insulin Resistance and Obesity, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Michigan · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 15, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
175
Ages
14 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Michigan.

Started
2023
with 2 others
Observational
2 of 38
1 open now
Registered
31st of 38
by date

Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, this one is one of 3 that started in 2023, is one of 2 observational ones, and was the 31st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 14 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, or all of them as a file.
02

Study summary

This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.

03

Conditions studied

  • Type 2 Diabetes
  • Insulin Resistance
  • Obesity
  • Metabolic Disease
  • PreDiabetes
04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants may be recruited from a variety of sites including University of Michigan clinical sites, non-University of Michigan clinical sites, local communities and schools throughout Southeast Michigan, and the University of Michigan campus.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 14 and 18 years of age
  • Tanner stage 4 or 5 (mature adult stage of puberty)
  • Normal weight ( ≥ 5th percentile \& \< 85th percentile), overweight (BMI > 86th percentile) \& \< 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes ( > 5.7%)
  • For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant
  • Use medications known to affect glucose metabolism ( medications, cancer medications, or high dose ), unless prescribed for Type 2 Diabetes management
  • Prior diagnosis of disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff
  • Allergies or intolerance to milk, soy, or palm oil
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
175 participants (estimated)
Patient registry
No

Groups and cohorts

  • Normal weight

    BMI ≥ 5th percentile \& \< 85th percentile

  • Obese weight

    BMI ≥ 95th percentile

  • PreDiabetes

    HbA1c \> 5.7%

  • Type 2 Diabetes

    Diagnosed with Type 2 Diabetes

  • Overweight

    BMI \> 86th percentile and \<94th percentile

06

What researchers measure

Primary outcomes

  1. Glucose (OGTT)

    Plasma Glucose (mg/dL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose

    Time frame: 120 minutes

  2. Insulin (OGTT)

    Plasma Insulin (µU/mL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose

    Time frame: 120 minutes

  3. Glucose (MMTT)

    Plasma Glucose (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake.

    Time frame: 180 minutes

  4. Insulin (MMTT)

    Plasma Insulin (µU/mL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake.

    Time frame: 180 minutes

  5. Monocyte /macrophage populations by flow cytometry

    Frequencies by flow cytometry. Measurements will be taken at baseline sample and 180 minutes after consumption of high fat shake

    Time frame: 180 minutes

Secondary outcomes

  1. Free fatty acids (MMTT)

    Serum Free fatty acids (mmol/L) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake

    Time frame: 180 minutes

  2. Triglycerides (MMTT)

    Serum Triglycerides (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake

    Time frame: 180 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Genomic and associated phenotypic data will be shared through NIH-designated data repositories.

Supporting information: Study protocol

Time frame: Genotype/sequencing and phenotype data will be submitted after the genotyping/sequencing data have been cleaned. Following submission, data will be released within six months.

Access criteria: In regards to genomic data, individual-level data will be deidentified and made available through controlled-access.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2023
First posted
Aug 23, 2023
StartActual
Sep 6, 2023
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Sep 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Dec 2026
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Oct 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06007404
Responsible party
Kanakadurga Singer (Associate Professor, University of Michigan) — Principal investigator
First posted
Aug 23, 2023
Start date
Sep 6, 2023
Primary completion
Dec 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

The Singer Lab Team
Contact
MiMoStudy@med.umich.edu
(734) 615-4938
Kanakadurga Singer, MA, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion